In Segment C, contributors will receive ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Contributors will acquire treatment until finally disease progression or the participants are unable to tolerate the study drugs. - "Our study disclosed the critical function with the KLF16/MYC regulatory axis in https://brd4-targeted-therapy-abb67801.pointblog.net/5-easy-facts-about-abbv-744-combination-therapy-with-chemotherapy-described-74596355